Applied Biosystems Sets Date for Special Meeting of Shareholders to Vote on Proposed Merger With Invitrogen Corporation

Applied Biosystems Inc. (NYSE:ABI) today announced it has set the date for a special meeting of its shareholders to consider the proposed merger with Invitrogen Corporation. The special meeting of shareholders will be held on October 16, 2008, at 9:30 a.m. EDT. Applied Biosystems shareholders of record as of the close of business on September 5, 2008 will be entitled to vote at the special meeting. The Company expects to commence mailing the proxy statement and all relevant materials to Applied Biosystems shareholders the week of September 8, 2008. Approval of both companies’ shareholders is a condition to the closing of the transaction. The transaction is also subject to the approval of the European Commission and other customary closing conditions. As previously announced on June 12, 2008, the Boards of Directors of Invitrogen and Applied Biosystems Inc. (formerly known as Applera Corporation) approved a definitive merger agreement under which Invitrogen will acquire all of the outstanding stock of Applied Biosystems Inc. in a cash and stock transaction valued at $6.7 billion. Shareholders who have questions about the merger, including their rights to elect to receive their merger consideration in all cash or all stock, subject to proration, or need assistance in submitting their proxy or voting their shares should contact the Company's proxy solicitor, Morrow & Co., Inc., toll-free at (800) 607-0088. About Applied Biosystems Inc. Applied Biosystems Inc. (formerly known as Applera Corporation) is a global leader in the development and marketing of instrument-based systems, consumables, software, and services for academic research, the life science industry and commercial markets. Driven by its employees' belief in the power of science to improve the human condition, the company commercializes innovative technology solutions for DNA, RNA, protein and small molecule analysis. Customers across the disciplines of academic and clinical research, pharmaceutical research and manufacturing, forensic DNA analysis, and agricultural biotechnology use the company’s tools and services to accelerate scientific discovery, improve processes related to drug discovery and development, detect potentially pathogenic microorganisms, and identify individuals based on DNA sources. Applied Biosystems has a comprehensive service and field applications support team for a global installed base of high-performance genetic and protein analysis solutions. Applied Biosystems Inc. is headquartered in Norwalk, CT. Information about Applied Biosystems, including reports and other information filed by the company with the Securities and Exchange Commission, is available at http://www.appliedbiosystems.com. All information in this news release is as of the date of the release, and Applied Biosystems does not undertake any duty to update this information unless required by law. ADDITIONAL INFORMATION AND WHERE TO FIND IT In connection with the proposed transaction, Invitrogen and Applied Biosystems have filed a proxy statement/prospectus as part of a registration statement on Form S-4 regarding the proposed transaction with the Securities and Exchange Commission, or SEC. The final joint proxy statement/prospectus will be mailed to shareholders of both companies. Investors and security holders are urged to read it in its entirety because it will contain important information about Invitrogen and Applied Biosystems and the proposed transaction. Investors and security holders may obtain a free copy of the definitive proxy statement/prospectus and other documents at the SEC’s web site at www.sec.gov. The definitive proxy statement/prospectus and other relevant documents may also be obtained free of charge from Applied Biosystems by directing such requests to: Applied Biosystems, Inc., Attention: Investor Relations 850 Lincoln Center Drive, Foster City, CA 94404. PARTICIPANTS IN THE SOLICITATION Invitrogen and Applied Biosystems and their respective directors, executive officers and certain other members of their management and employees may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Information concerning all of the participants in the solicitation is included in the proxy statement relating to the proposed merger. Each of these documents is, or will be, available free of charge at the Securities and Exchange Commission’s web site at http://www.sec.gov and from Applied Biosystems Investor Relations, telephone: (650) 554-2449 or on Applied Biosystems’ web site at http://www.appliedbiosystems.com.